Product Name:  Micotil 300, 50 ml

Description: 

Description: Micotil® 300 is a solution of the antibiotic tilmicosin. Each mL contains 300 mg of tilmicosin, USP as tilmicosin phosphate in 25% propylene glycol, phosphoric acid as needed to adjust pH and water for injection, Q.S.

Tilmicosin, USP is produced semi-synthetically and is in the macrolide class of antibiotics.

Actions: Activity-Tilmicosin has an in-vitro** antibacterial spectrum that is predominantly gram-positive with activity against certain gram-negative microorganisms. Activity against several mycoplasma species has also been detected.

Ninety-five percent of the Mannheimia (Pasteurella) haemolytica isolates were inhibited by 3.12 µg/mL or less.

**The clinical significance of this in-vitro data in cattle and sheep has not been demonstrated.

Toxicology: The heart is the target of toxicity in laboratory and domestic animals given Micotil® 300 by oral or parenteral routes. The primary cardiac effects are increased heart rate (tachycardia) and decreased contractility (negative inotropy).

Upon injection subcutaneously, the acute median lethal dose of tilmicosin in mice is 97 mg/kg, and in rats is 185 mg/kg of body weight. Given orally, the median lethal dose is 800 mg/kg and 2250 mg/kg in fasted and nonfasted rats, respectively. No compound-related lesions were found at necropsy.

In monkeys, a single intramuscular dose of 10 mg/kg caused no signs of toxicity. A single dose of 20 mg/kg caused vomiting and 30 mg/kg caused the death of the only monkey tested.

In swine, intramuscular injection of 10 mg/kg caused increased respiration, emesis, and a convulsion; 20 mg/kg resulted in mortality in 3 of 4 pigs; and 30 mg/kg caused the death of all 4 pigs tested.

Results of genetic toxicology studies were all negative. Results of teratology and reproduction studies in rats were negative. The no effect level in dogs after daily oral doses for up to one year is 4 mg/kg of body weight.

In cattle, subcutaneous doses of 10, 30, and 50 mg/kg of body weight, each injected 3 times at 72-hour intervals did not cause any deaths. As expected, edema at the site of injection was noted. The only lesion observed at necropsy was minimal myocardial necrosis in some animals in the 50 mg/kg group. Subcutaneous doses of 150 mg/kg injected at 72-hour intervals resulted in deaths. Edema was marked at the site of injection. Minimal myocardial necrosis was the only lesion observed at necropsy. Deaths of cattle have been observed with a single intravenous dose of 5 mg/kg of body weight.

In sheep, single subcutaneous injections of 10 mg/kg dose did not cause any deaths and no adverse effects of tilmicosin were observed on blood pressure, heart rate, or respiratory rate.

Pharmacology: A single subcutaneous injection of Micotil® 300 at 10 mg/kg of body weight dose in cattle resulted in peak tilmicosin levels within one hour and detectable levels (0.07 µg/mL) in serum beyond 3 days. However, lung concentrations of tilmicosin remained above the tilmicosin MIC 95% of 3.12 µg/mL for Mannheimia (Pasteurella) haemolytica for at least 3 days following the single injection. Serum tilmicosin levels are a poor indicator of total body tilmicosin. The lung/serum tilmicosin ratio in favor of lung tissue appeared to equilibrate by 3 days post injection at approximately 60. In a study with radioactive tilmicosin, 24% and 68% of the dose was recovered from urine and feces, respectively, over 21 days.

Directions-Inject Subcutaneously in Cattle and Sheep Only. Administer a single subcutaneous dose of 10 mg/kg of body weight (1 mL/30 kg or 1.5 mL/100 lbs). Do not inject more than 15 mL per injection site.

Do not use in lambs less than 15 kg body weight.

If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

For cattle and sheep, injection under the skin in the neck is suggested. If not accessible, inject under the skin behind the shoulders and over the ribs.

For sheep, injection in a skin fold behind the shoulders and over the ribs is suggested.

Note: Swelling at the subcutaneous site of injection may be observed but is transient and usually mild.

Contraindication: Do not use in automatically powered syringes. Do not administer intravenously to cattle or sheep. Intravenous injection in cattle or sheep will be fatal. Do not administer to animals other than cattle or sheep. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats.

CAUTION: Read accompanying literature fully before use. Do Not Administer to Swine. Injection in Swine Has Been Shown to be Fatal. The safety of tilmicosin has not been established in pregnant cattle and in animals used for breeding purposes. Intramuscular injection will cause a local reaction which may result in trim loss. The safety of tilmicosin has not been established for sheep with a body weight of less than 15 kg or in pregnant sheep or sheep used for breeding purposes.

How Supplied: Micotil is supplied in 50 mL, 100 mL and 250 mL multidose amber glass bottles.

Storage: Store at or below 86°F (30°C). Protect from direct sunlight.

Conservar a 86°F (30°C). Protejer de la directa luz solar.

*Elanco®, Micotil® and the diagonal color bar are trademarks of Eli Lilly and Company.

To report adverse effects, access medical information, or obtain additional product information, call 1-800-428-4441.

Revised September 2003

Manufactured for: Elanco Animal Health

A Division of Eli Lilly and Company

Indianapolis, IN 46285, USA